LivingGLP1
parallel randomized trial

S003012

Design

Randomized
223
Start year
2025
Treatment
24 weeks, follow-up 24 weeks
Countries
India (29 sites)
Sponsor
(industry)
Eligibility
age 18 to 65; HbA1c 7 to <10.5%; metformin 1500 mg/day or more

Conduct and analysis

Blinding
open label
Sequence generation
other adequate
Allocation concealment
central
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
modified itt
Missing data
LOCF

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1semaglutide
Test product (Intas semaglutide)
metformin; lifestyle: standard112108
A2semaglutide
Reference product (Novo Nordisk semaglutide)
metformin; lifestyle: standard111109

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticTest product (Intas semaglutide)
A1
Reference product (Novo Nordisk semaglutide)
A2
agemean (years)4948
agesd (years)10.210.4
bmimean (kg/m2)30.830.5
bmisd (kg/m2)5.65.1
diabetes durationmean (months)4442
femalen4658
femalepercent42.653.2
hba1cmean (percent)8.48.4
hba1csd (percent)1.00.9
weightmean (kg)80.779.1
weightsd (kg)15.716.7

Results

37 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (8 lines; O01)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1change-1.50 percent108not stated; modified itt; R0014460:Table 2
24A1change-1.51 percent108not stated; modified itt; R0014460:Table 2
24A1change-1.54 percent105not stated; per protocol; R0014460:Supplement Table 1
24A1 vs A2md0.16 percent-0.16 to 0.47not stated; modified itt; R0014460:Table 2
24A1 vs A2md0.15 percent-0.16 to 0.46not stated; per protocol; R0014460:Supplement Table 1
24A2change-1.65 percent109not stated; modified itt; R0014460:Table 2
24A2change-1.63 percent109not stated; modified itt; R0014460:Table 2
24A2change-1.69 percent100not stated; per protocol; R0014460:Supplement Table 1
Body weight change in kilograms (diabetes) (2 lines; O02)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1change-6.0 kg3.3not stated; modified itt; R0014460:Results
24A2change-5.8 kg3.7not stated; modified itt; R0014460:Results
Level 2 or 3 hypoglycemia (participants) (2 lines; O04)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events6 / 112not stated; safety; R0014460:Table 3
A2events7 / 111not stated; safety; R0014460:Table 3
Weight loss of 5 percent or more (2 lines; O11A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1responders69.4108not stated; modified itt; R0014460:Results
24A2responders66.1109not stated; modified itt; R0014460:Results
Weight loss of 10 percent or more (2 lines; O11B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1responders19.4108not stated; modified itt; R0014460:Results
24A2responders15.6109not stated; modified itt; R0014460:Results
Acute kidney injury (1 lines; O121)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A2events0 / 111not stated; safety; R0014460:Table 3
All cause mortality (2 lines; O20)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3
Hospitalization for heart failure (2 lines; O23)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3
Serious adverse events (2 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3
Discontinuation due to adverse events (2 lines; O26)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3
Nausea (2 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events8 / 112not stated; safety; R0014460:Table 3
A2events9 / 111not stated; safety; R0014460:Table 3
Vomiting (2 lines; O27B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events7 / 112not stated; safety; R0014460:Table 3
A2events10 / 111not stated; safety; R0014460:Table 3
Diarrhea (2 lines; O27C)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events7 / 112not stated; safety; R0014460:Table 3
A2events10 / 111not stated; safety; R0014460:Table 3
Constipation (2 lines; O27D)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events7 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3
Discontinuation due to gastrointestinal adverse events (2 lines; O27E)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3
Death by suicide (2 lines; O35B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 112not stated; safety; R0014460:Table 3
A2events0 / 111not stated; safety; R0014460:Table 3